These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22824780)

  • 1. PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting.
    Kim TH; Jo YG; Jiang HH; Lim SM; Youn YS; Lee S; Chen X; Byun Y; Lee KC
    J Control Release; 2012 Sep; 162(2):422-8. PubMed ID: 22824780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
    Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
    Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity.
    Kim TH; Jiang HH; Park CW; Youn YS; Lee S; Chen X; Lee KC
    J Control Release; 2011 Feb; 150(1):63-9. PubMed ID: 21062635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.
    Oh Y; Swierczewska M; Kim TH; Lim SM; Eom HN; Park JH; Na DH; Kim K; Lee KC; Pomper MG; Lee S
    J Control Release; 2015 Dec; 220(Pt B):671-81. PubMed ID: 26381901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects.
    Kim TH; Youn YS; Jiang HH; Lee S; Chen X; Lee KC
    Bioconjug Chem; 2011 Aug; 22(8):1631-7. PubMed ID: 21751817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transferrin Conjugated pH- and Redox-Responsive Poly(Amidoamine) Dendrimer Conjugate as an Efficient Drug Delivery Carrier for Cancer Therapy.
    Hu Q; Wang Y; Xu L; Chen D; Cheng L
    Int J Nanomedicine; 2020; 15():2751-2764. PubMed ID: 32368053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active tumor-targeted delivery of PEG-protein via transferrin-transferrin-receptor system.
    Jiang Y; Tang G; Hong M; Zhu S; Fang C; Shi B; Pei Y
    J Drug Target; 2007 Dec; 15(10):672-83. PubMed ID: 18041635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conjugation to 10 kDa Linear PEG Extends Serum Half-Life and Preserves the Receptor-Binding Ability of mmTRAIL with Minimal Stimulation of PEG-Specific Antibodies.
    Nie Q; Jia D; Yang H; Feng Y; Fan Q; Shi Q; Wan L; Lu X
    Mol Pharm; 2017 Feb; 14(2):502-512. PubMed ID: 28029256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand.
    Chae SY; Kim TH; Park K; Jin CH; Son S; Lee S; Youn YS; Kim K; Jo DG; Kwon IC; Chen X; Lee KC
    Mol Cancer Ther; 2010 Jun; 9(6):1719-29. PubMed ID: 20515949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing Multistep Delivery of PEGylated Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand-Toxin Conjugates for Improved Antitumor Activities.
    Wei X; Yang X; Zhao W; Xu Y; Pan L; Chen S
    Bioconjug Chem; 2017 Aug; 28(8):2180-2189. PubMed ID: 28697305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).
    Pan LQ; Wang HB; Lai J; Xu YC; Zhang C; Chen SQ
    Biomaterials; 2013 Dec; 34(36):9115-23. PubMed ID: 23981355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities.
    Pan LQ; Zhao WB; Lai J; Ding D; Wei XY; Li YY; Liu WH; Yang XY; Xu YC; Chen SQ
    Sci Rep; 2015 Oct; 5():14872. PubMed ID: 26445897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer.
    Iinuma H; Maruyama K; Okinaga K; Sasaki K; Sekine T; Ishida O; Ogiwara N; Johkura K; Yonemura Y
    Int J Cancer; 2002 May; 99(1):130-7. PubMed ID: 11948504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo.
    Ishida O; Maruyama K; Tanahashi H; Iwatsuru M; Sasaki K; Eriguchi M; Yanagie H
    Pharm Res; 2001 Jul; 18(7):1042-8. PubMed ID: 11496943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles.
    Lim SM; Kim TH; Jiang HH; Park CW; Lee S; Chen X; Lee KC
    Biomaterials; 2011 May; 32(13):3538-46. PubMed ID: 21306770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model.
    Byeon HJ; Choi SH; Choi JS; Kim TH; Lee ES; Lee KC; Youn YS
    Biomed Pharmacother; 2014 Feb; 68(1):65-9. PubMed ID: 24268811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo.
    Hatakeyama H; Akita H; Maruyama K; Suhara T; Harashima H
    Int J Pharm; 2004 Aug; 281(1-2):25-33. PubMed ID: 15288340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy.
    Jiang HH; Kim TH; Lee S; Chen X; Youn YS; Lee KC
    Biomaterials; 2011 Nov; 32(33):8529-37. PubMed ID: 21855130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.
    Hong M; Zhu S; Jiang Y; Tang G; Sun C; Fang C; Shi B; Pei Y
    J Control Release; 2010 Jan; 141(1):22-9. PubMed ID: 19735683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF3L fusion enhances the antitumor activity of TRAIL by promoting assembly into polymers.
    Wang Y; Lei Q; Yan Z; Shen C; Wang N
    Biochem Pharmacol; 2018 Sep; 155():510-523. PubMed ID: 30059675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.